Lv1
26 积分 2024-03-27 加入
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
1个月前
已完结
Rational combinations of targeted cancer therapies: background, advances and challenges
1个月前
已完结
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
1个月前
已完结
MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells
3个月前
已完结
RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer
3个月前
已完结
Bispecific T-cell Engager (CD3 × EGFR)-Based Triplet Therapy Unlocks CD40/CD40L Crosstalk to Revert Immunosuppression in Third-Generation EGFR-Tyrosine Kinase Inhibitor–Refractory NSCLC
3个月前
已完结
RTN4IP1 Contributes to ESCC via Regulation of Amino Acid Transporters
3个月前
已完结
Targeting CLK1/SRSF7 axis-dependent alternative splicing sensitizes pancreatic ductal adenocarcinoma to chemotherapy and immunotherapy
4个月前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
4个月前
已完结
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
4个月前
已完结
皖公网安备34019202002308
